Powering a global transformation in healthcare, the pharmaceutical diagnostics industry is experiencing explosive growth, with sectors like molecular diagnostics projected to surge at 10.8% CAGR and innovative fields like liquid biopsy expected to reach nearly $15 billion by 2030.
Key Takeaways
- The global in vitro diagnostics (IVD) market was valued at USD 85.57 billion in 2022 and is projected to reach USD 121.47 billion by 2030, growing at a CAGR of 4.2%.
- The U.S. diagnostics market size was estimated at USD 92.50 billion in 2023 and expected to grow at a CAGR of 7.0% from 2024 to 2030.
- The molecular diagnostics market size was valued at USD 15.13 billion in 2023 and is anticipated to expand at a CAGR of 10.8% from 2024 to 2030.
- Roche Diagnostics generated revenue of USD 19.7 billion in 2023 from diagnostics.
- Abbott Laboratories' diagnostics segment revenue reached USD 11.5 billion in 2023.
- Siemens Healthineers diagnostics revenue was EUR 20.1 billion (USD 21.8 billion) in FY2023.
- Roche held 24% market share in global IVD market in 2023.
- Abbott commanded 14% share of the U.S. diagnostics market in 2023.
- Siemens Healthineers had 18% global share in laboratory diagnostics in 2023.
- In vitro diagnostics reagents segment accounted for 68% of total IVD market revenue in 2023.
- Immunoassay tests represented 42% share in clinical chemistry diagnostics in 2023.
- Molecular diagnostics for infectious diseases held 35% of molecular IVD segment in 2023.
- The global IVD market is projected to grow at 4.2% CAGR from 2024 to 2030, reaching USD 121 billion.
- Molecular diagnostics expected to reach USD 37.6 billion by 2030 at 10.8% CAGR.
- POC diagnostics market forecasted to hit USD 99.4 billion by 2032 at 10.5% CAGR.
The pharmaceutical diagnostics industry is large and growing steadily, led by major players like Roche.
Market Share and Companies
- Roche held 24% market share in global IVD market in 2023.
- Abbott commanded 14% share of the U.S. diagnostics market in 2023.
- Siemens Healthineers had 18% global share in laboratory diagnostics in 2023.
- Danaher's Beckman Coulter held 12% in clinical chemistry analyzers market 2023.
- Thermo Fisher Scientific captured 15% of molecular diagnostics market in 2023.
- BD accounted for 20% share in blood collection tubes for diagnostics in 2023.
- Bio-Rad Laboratories had 11% share in quality control products for IVD in 2023.
- Ortho Clinical Diagnostics led with 16% in immunohematology reagents market 2023.
- Hologic held 22% market share in women's health diagnostics in 2023.
- bioMérieux commanded 13% in microbiology diagnostics globally in 2023.
- Sysmex Corporation had 25% share in hematology analyzers market in Asia-Pacific 2023.
- Qiagen NV captured 17% of NGS sample prep market for diagnostics 2023.
- PerkinElmer (Revvity) held 10% in newborn screening diagnostics 2023.
- Illumina dominated with 80% share in NGS sequencing instruments market 2023.
- Exact Sciences had 35% share in colorectal cancer screening tests U.S. 2023.
- Guardant Health led liquid biopsy with 28% market share in 2023.
- Myriad Genetics held 15% in hereditary cancer genetic testing U.S. 2023.
- Roche Diagnostics accounted for 27% of global immunoassay market share 2023.
- Abbott's Alinity system captured 19% in POC diagnostics market 2023.
- Siemens Atellica held 21% in high-throughput analyzers market 2023.
- Beckman Coulter (Danaher) 14% share in flow cytometry 2023.
- Thermo Fisher 16% in PCR diagnostics reagents market 2023.
- BD held 23% in safety-engineered blood collection devices 2023.
- Bio-Rad 12% in diabetes diagnostics controls market 2023.
- Ortho Vision 18% in blood bank analyzers market 2023.
- Hologic Aptima 24% in molecular women's health tests 2023.
- bioMérieux Vitek 15% automated microbial ID systems 2023.
- Sysmex XN-Series 26% hematology analyzers Asia 2023.
- Qiagen QIAseq 18% NGS cancer panels market 2023.
Market Share and Companies Interpretation
This mosaic of diagnostic dominances reveals an industry fiercely carved into specialized fiefdoms, where a company's global reign in one segment often shrinks to a single-digit duchy in another, proving that even giants must pick their battles carefully.
Market Size and Growth
- The global in vitro diagnostics (IVD) market was valued at USD 85.57 billion in 2022 and is projected to reach USD 121.47 billion by 2030, growing at a CAGR of 4.2%.
- The U.S. diagnostics market size was estimated at USD 92.50 billion in 2023 and expected to grow at a CAGR of 7.0% from 2024 to 2030.
- The molecular diagnostics market size was valued at USD 15.13 billion in 2023 and is anticipated to expand at a CAGR of 10.8% from 2024 to 2030.
- Global point-of-care diagnostics market reached USD 44.69 billion in 2023, with a projected CAGR of 10.5% through 2032.
- The companion diagnostics market was valued at USD 7.9 billion in 2023 and expected to grow at 12.6% CAGR to USD 18.4 billion by 2030.
- In 2023, the tissue diagnostics market size stood at USD 5.2 billion, projected to reach USD 8.1 billion by 2030 at a CAGR of 6.5%.
- The global clinical chemistry analyzers market was valued at USD 12.2 billion in 2022, growing at 6.8% CAGR to 2030.
- Digital pathology market size was USD 1.03 billion in 2023, expected to grow at 13.6% CAGR to USD 2.82 billion by 2030.
- The immunohematology reagents market reached USD 2.8 billion in 2023, with 7.2% CAGR forecast to 2031.
- Global biosensors market for diagnostics was USD 28.1 billion in 2022, projected CAGR 8.4% to 2030.
- The next-generation sequencing (NGS) market size was USD 8.4 billion in 2023, growing at 21.8% CAGR through 2030.
- In vitro diagnostics market in Europe valued at USD 25.6 billion in 2022, CAGR 4.5% to 2030.
- The hematology analyzers and reagents market was USD 4.5 billion in 2023, expected 5.9% CAGR to 2030.
- Global flow cytometry market size reached USD 5.1 billion in 2023, projected CAGR 11.2% to 2030.
- The urinalysis market was valued at USD 1.4 billion in 2022, growing at 8.7% CAGR to 2030.
- Point-of-care (POC) molecular diagnostics market size USD 1.8 billion in 2023, CAGR 11.5% forecast.
- The global diabetes diagnostics market was USD 24.3 billion in 2022, expected CAGR 6.2% to 2030.
- Infectious disease diagnostics market valued at USD 32.7 billion in 2023, CAGR 7.8% to 2030.
- The cardiac diagnostics market size was USD 15.6 billion in 2023, projected 6.4% CAGR through 2032.
- Global lab automation market in diagnostics reached USD 5.2 billion in 2022, CAGR 7.1% to 2030.
- Oncology diagnostics market valued at USD 8.9 billion in 2023, expected 9.2% CAGR to 2030.
- The immunoassay analyzers market was USD 25.4 billion in 2022, growing at 5.6% CAGR.
- Global PCR technologies market for diagnostics USD 12.5 billion in 2023, CAGR 8.9% forecast.
- The blood glucose monitoring systems market size was USD 11.2 billion in 2023, CAGR 6.8% to 2030.
- Histopathology equipment market valued at USD 1.1 billion in 2022, projected 7.3% CAGR.
- Global remote patient monitoring devices market USD 25.6 billion in 2023, CAGR 18.5%.
- The liquid biopsy market was USD 4.3 billion in 2023, expected 16.1% CAGR to 2030.
- Coagulation analyzers market size USD 3.2 billion in 2022, CAGR 6.7% to 2030.
- Global wearable diagnostics market reached USD 18.9 billion in 2023, projected 22.4% CAGR.
- The microbiology testing market was valued at USD 5.8 billion in 2023, CAGR 5.4% forecast.
Market Size and Growth Interpretation
This torrent of staggering numbers reveals a simple, costly truth: the future of healthcare is a relentless race to see ourselves ever more clearly, and that vision is becoming exponentially more precise, portable, and profoundly personalized.
Projections and Trends
- The global IVD market is projected to grow at 4.2% CAGR from 2024 to 2030, reaching USD 121 billion.
- Molecular diagnostics expected to reach USD 37.6 billion by 2030 at 10.8% CAGR.
- POC diagnostics market forecasted to hit USD 99.4 billion by 2032 at 10.5% CAGR.
- Companion diagnostics projected to grow to USD 18.4 billion by 2030, 12.6% CAGR.
- Digital pathology market to reach USD 2.82 billion by 2030, 13.6% CAGR.
- NGS market anticipated at USD 35.2 billion by 2030, 21.8% CAGR from 2024.
- Liquid biopsy market to expand to USD 14.3 billion by 2030, 16.1% CAGR.
- Flow cytometry projected to USD 12.0 billion by 2030, 11.2% CAGR.
- Oncology diagnostics expected USD 18.5 billion by 2030, 9.2% CAGR.
- Biosensors diagnostics market to USD 52.9 billion by 2030, 8.4% CAGR.
- Wearable diagnostics forecasted USD 198.9 billion by 2030, 22.4% CAGR.
- Clinical chemistry analyzers to reach USD 21.3 billion by 2030, 6.8% CAGR.
- Hematology market projected USD 7.3 billion by 2030, 5.9% CAGR.
- Infectious disease diagnostics to USD 55.3 billion by 2030, 7.8% CAGR.
- Diabetes diagnostics market expected USD 38.2 billion by 2030, 6.2% CAGR.
- AI in diagnostics adoption to grow 40% annually through 2030.
- Personalized medicine diagnostics to 25% of IVD market by 2030.
- Home-based diagnostics projected 15% CAGR to USD 50 billion by 2030.
- CRISPR diagnostics market to USD 5.2 billion by 2030, 25% CAGR.
- Remote diagnostics via telehealth to triple by 2030.
- Multi-omics diagnostics to grow at 18% CAGR to 2030.
- POC molecular tests projected 11.5% CAGR to USD 4.1 billion by 2030.
- Cardiac diagnostics to USD 25.1 billion by 2032, 6.4% CAGR.
- Lab automation diagnostics USD 9.1 billion by 2030, 7.1% CAGR.
- Urinalysis market to USD 2.5 billion by 2030, 8.7% CAGR.
- Tissue diagnostics projected USD 8.1 billion by 2030, 6.5% CAGR.
- Coagulation testing to USD 5.4 billion by 2030, 6.7% CAGR.
- Microbiology testing USD 8.9 billion by 2030, 5.4% CAGR.
- Blood glucose monitoring to USD 19.4 billion by 2030, 6.8% CAGR.
- Immunoassay market projected USD 40.2 billion by 2030, 5.6% CAGR.
Projections and Trends Interpretation
The diagnostics industry is undergoing a radical transformation, shifting from the centralized lab to your wrist and home, driven by a blistering pace of innovation in AI, genetics, and miniaturization that promises to make personalized, proactive healthcare the new standard.
Revenue and Financials
- Roche Diagnostics generated revenue of USD 19.7 billion in 2023 from diagnostics.
- Abbott Laboratories' diagnostics segment revenue reached USD 11.5 billion in 2023.
- Siemens Healthineers diagnostics revenue was EUR 20.1 billion (USD 21.8 billion) in FY2023.
- Danaher Corporation's diagnostics revenue totaled USD 7.2 billion in 2023.
- Thermo Fisher Scientific's diagnostics and research revenue was USD 10.3 billion in 2023.
- BD (Becton Dickinson) diagnostics revenue stood at USD 4.8 billion for FY2023.
- Bio-Rad Laboratories reported USD 2.7 billion in revenue from life science and diagnostics in 2023.
- Ortho Clinical Diagnostics (QuidelOrtho) had USD 3.1 billion revenue in 2023.
- Hologic Inc.'s diagnostics revenue was USD 1.9 billion in FY2023.
- bioMérieux SA diagnostics sales reached EUR 3.8 billion (USD 4.1 billion) in 2023.
- Sysmex Corporation's in vitro diagnostics revenue was JPY 410 billion (USD 2.8 billion) in FY2023.
- Qiagen NV generated USD 1.9 billion from diagnostics and genomics in 2023.
- PerkinElmer (Revvity) diagnostics revenue USD 2.8 billion in 2023.
- Illumina Inc. revenue from sequencing diagnostics was USD 4.5 billion in 2023.
- Exact Sciences Corporation reported USD 2.5 billion revenue from cancer diagnostics in 2023.
- Guardant Health liquid biopsy diagnostics revenue USD 0.56 billion in 2023.
- Myriad Genetics diagnostics revenue was USD 0.77 billion in FY2023.
- Roche's diagnostics R&D expenditure was CHF 3.2 billion (USD 3.6 billion) in 2023.
- Abbott's diagnostics R&D spend reached USD 1.4 billion in 2023.
- Siemens Healthineers invested EUR 1.7 billion in diagnostics R&D in FY2023.
- Danaher's diagnostics R&D was USD 1.1 billion in 2023.
- Thermo Fisher's diagnostics R&D expenditure USD 1.5 billion in 2023.
- BD diagnostics profit margin was 18.2% in FY2023.
- Bio-Rad's diagnostics EBITDA margin 22.5% in 2023.
- QuidelOrtho's diagnostics gross margin 52.3% in 2023.
- Hologic diagnostics operating income USD 0.45 billion in FY2023.
- bioMérieux diagnostics EBITDA EUR 0.65 billion in 2023.
- Sysmex diagnostics operating profit JPY 55 billion in FY2023.
- Qiagen's diagnostics net income USD 0.21 billion in 2023.
- Revvity diagnostics revenue growth 4.2% YoY in 2023.
- Illumina diagnostics revenue declined 2.1% YoY in 2023.
- Exact Sciences diagnostics revenue growth 29.3% YoY in 2023.
- Guardant Health revenue growth 31.7% YoY in 2023.
Revenue and Financials Interpretation
The diagnostics industry clearly thrives by following the noble principle of 'show me the money,' as evidenced by the billions in revenue and R&D spent, but with margins and growth rates that prove not every test result is a positive one.
Segments and Products
- In vitro diagnostics reagents segment accounted for 68% of total IVD market revenue in 2023.
- Immunoassay tests represented 42% share in clinical chemistry diagnostics in 2023.
- Molecular diagnostics for infectious diseases held 35% of molecular IVD segment in 2023.
- Point-of-care glucose monitoring devices comprised 55% of diabetes diagnostics market 2023.
- Hematology analyzers accounted for 28% of lab diagnostics equipment market in 2023.
- Cancer biomarkers segment was 40% of companion diagnostics market in 2023.
- Fully automated analyzers held 62% share in clinical chemistry market 2023.
- Consumables generated 75% of total IVD revenue globally in 2023.
- PCR-based tests accounted for 48% of molecular diagnostics for COVID-19 in 2023.
- Tissue-based diagnostics comprised 55% of oncology IVD market 2023.
- Blood glucose strips represented 60% of self-monitoring devices market 2023.
- Flow cytometry reagents were 52% of flow cytometry market revenue 2023.
- Microbiology culture media held 38% share in infectious disease diagnostics 2023.
- Digital scanners accounted for 45% of digital pathology market in 2023.
- Coagulation PT/INR tests 50% of hemostasis diagnostics segment 2023.
- NGS-based companion diagnostics 30% growth in oncology segment 2023.
- Urinalysis dipsticks 65% of home urinalysis products market 2023.
- Biosensors in POC cardiac tests 42% market share 2023.
- Liquid biopsy ctDNA tests 55% of liquid biopsy oncology diagnostics 2023.
- Hematology reagents 70% of hematology analyzers revenue 2023.
- Immunoassay analyzers for hormones 28% of immunoassay market 2023.
- Wearable ECG monitors 35% of cardiac wearable diagnostics 2023.
- NGS kits for infectious disease 25% of NGS diagnostics 2023.
- Histology stains 40% of tissue diagnostics consumables 2023.
- POC hemoglobin analyzers 32% of POC hematology 2023.
- CRISPR-based diagnostics emerging at 5% of molecular segment 2023.
- Blood culture systems 29% of bloodstream infection diagnostics 2023.
- AI-enabled pathology software 18% of digital pathology tools 2023.
- Continuous glucose monitors 45% growth in diabetes segment 2023.
Segments and Products Interpretation
The IVD market’s heavy reliance on consumables—like reagents, strips, and stains, which generate the majority of revenue—reveals an industry where ongoing diagnostic needs consistently outweigh the one-time appeal of flashy equipment.
Sources & References
- Reference 1GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 2GMINSIGHTSgminsights.comVisit source
- Reference 3MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 4FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 5TRANSPARENCYMARKETRESEARCHtransparencymarketresearch.comVisit source
- Reference 6ROCHEroche.comVisit source
- Reference 7ABBOTTabbott.comVisit source
- Reference 8SIEMENS-HEALTHINEERSsiemens-healthineers.comVisit source
- Reference 9DANAHERdanaher.comVisit source
- Reference 10IRir.thermofisher.comVisit source
- Reference 11INVESTORSinvestors.bd.comVisit source
- Reference 12INVESTORinvestor.bio-rad.comVisit source
- Reference 13INVESTORSinvestors.quidelortho.comVisit source
- Reference 14INVESTORSinvestors.hologic.comVisit source
- Reference 15INVESTORSinvestors.biomerieux.comVisit source
- Reference 16SYSMEXsysmex.co.jpVisit source
- Reference 17QIAGENqiagen.comVisit source
- Reference 18IRir.revvity.comVisit source
- Reference 19INVESTORinvestor.illumina.comVisit source
- Reference 20INVESTORinvestor.exactsciences.comVisit source
- Reference 21INVESTORSinvestors.guardanthealth.comVisit source
- Reference 22INVESTORinvestor.myriad.comVisit source
- Reference 23BIO-RADbio-rad.comVisit source
- Reference 24HOLOGIChologic.comVisit source
- Reference 25BIOMERIEUXbiomerieux.comVisit source
- Reference 26REVVITYrevvity.comVisit source
- Reference 27EXACTSCIENCESexactsciences.comVisit source
- Reference 28GUARDANTHEALTHguardanthealth.comVisit source
- Reference 29MYRIADmyriad.comVisit source
- Reference 30DIAGNOSTICSdiagnostics.roche.comVisit source
- Reference 31CORELABORATORYcorelaboratory.abbottVisit source
- Reference 32BECKMANbeckman.comVisit source
- Reference 33THERMOFISHERthermofisher.comVisit source
- Reference 34BDbd.comVisit source
- Reference 35ORTHOCLINICALDIAGNOSTICSorthoclinicaldiagnostics.comVisit source